{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:33:15Z","timestamp":1744716795529},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.diabres.2011.11.016","type":"journal-article","created":{"date-parts":[[2011,12,12]],"date-time":"2011-12-12T12:25:06Z","timestamp":1323692706000},"page":"e52-e54","source":"Crossref","is-referenced-by-count":11,"title":["Pegylated interferon-\u03b12b and ribavirin combination therapy induces Hashitoxicosis followed by type 1 diabetes mellitus"],"prefix":"10.1016","volume":"95","author":[{"given":"Hiroaki","family":"Yagyu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobukazu","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-ichi","family":"Osuga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichiro","family":"Nagasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Sugano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2011.11.016_bib0005","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1111\/j.1572-0241.2000.03223.x","article-title":"Hyperthyroidism with interferon-ribavirin therapy for hepatitis C: a case report and proposed treatment algorithm","volume":"95","author":"Harris","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.diabres.2011.11.016_bib0010","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.diabres.2009.08.009","article-title":"Dual onset of type 1 diabetes mellitus and Graves\u2019 disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C","volume":"86","author":"Hayashi","year":"2009","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2011.11.016_bib0015","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.3748\/wjg.v13.i8.1292","article-title":"Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C","volume":"13","author":"Soultati","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.diabres.2011.11.016_bib0020","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJM198612183152503","article-title":"Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report","volume":"315","author":"Hoofnagle","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2011.11.016_bib0025","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.21146","article-title":"The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification","volume":"43","author":"Mandac","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2011.11.016_bib0030","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1530\/eje.0.1320587","article-title":"Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a","volume":"132","author":"Preziati","year":"1995","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.diabres.2011.11.016_bib0035","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0002-9343(96)00259-8","article-title":"Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha","volume":"101","author":"Roti","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.diabres.2011.11.016_bib0040","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/0140-6736(92)91744-S","article-title":"Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis","volume":"340","author":"Fabris","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2011.11.016_bib0045","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.2169\/internalmedicine.48.2220","article-title":"Peginterferon (PEG-IFN) plus ribavirin combination therapy, but neither interferon nor PGE-IFN alone, induced type 1 diabetes in a patient with chronic hepatitis C","volume":"48","author":"Ogihara","year":"2009","journal-title":"Intern Med"},{"key":"10.1016\/j.diabres.2011.11.016_bib0050","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0168-8278(96)80113-9","article-title":"Side effects of high-dose interferon therapy for chronic hepatitis C","volume":"25","author":"Okanoue","year":"1996","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabres.2011.11.016_bib0055","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0168-8227(00)00143-1","article-title":"A case of chronic hepatitis C developing insulin-dependent diabetes mellitus associated with various autoantibodies during interferon therapy","volume":"49","author":"Uto","year":"2000","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2011.11.016_bib0060","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0168-8278(96)80184-X","article-title":"A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon","volume":"24","author":"Fattovich","year":"1996","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabres.2011.11.016_bib0065","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2337\/diab.38.5.641","article-title":"Effect of interferon on glucose tolerance and insulin sensitivity","volume":"38","author":"Koivisto","year":"1989","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2011.11.016_bib0070","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clim.2004.01.008","article-title":"Interferon alpha \u2013 a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity","volume":"111","author":"Devendra","year":"2004","journal-title":"Clin Immunol"},{"key":"10.1016\/j.diabres.2011.11.016_bib0075","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF00400427","article-title":"IDDM: comment","volume":"39","author":"Foulis","year":"1996","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2011.11.016_bib0080","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1210\/jc.2005-0093","article-title":"Innate and acquired immune system in patients developing interferon-alpha-related autoimmune thyroiditis: a prospective study","volume":"90","author":"Mazziotti","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2011.11.016_bib0085","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1089\/105072503322238809","article-title":"Interferon-alpha and autoimmune thyroid disease","volume":"13","author":"Prummel","year":"2003","journal-title":"Thyroid"},{"key":"10.1016\/j.diabres.2011.11.016_bib0090","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2337\/dc09-9033","article-title":"International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes","volume":"32","author":"International Expert Committee","year":"2009","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.diabres.2011.11.016_bib0095","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.2337\/dc10-S062","article-title":"Diagnosis and classification of diabetes mellitus","volume":"33","author":"American Diabetes Association","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2011.11.016_bib0100","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0016-5085(00)70217-4","article-title":"C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C","volume":"118","author":"Cramp","year":"2000","journal-title":"Gastroenterology"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822711006395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822711006395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T18:32:04Z","timestamp":1686508324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822711006395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0168822711006395"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2011.11.016","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}